Cargando…

Correction to: Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia

Detalles Bibliográficos
Autores principales:	Chandrakala, S., Toshniwal, Manoj, Halvawala, Mitesh, Padwal, Namita, Sidharthan, Neeraj, Malhotra, Pankaj, Prashantha, B., Ballikar, Riya, Shah, Sandip, Apte, Shashikant, Viswanathan, T. Kasi, Ramanan, Vijay, Sharma, Akhilesh, Pawar, Dattatray, Pawar, Roshan, Shahavi, Vinayaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer India 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10247629/ https://www.ncbi.nlm.nih.gov/pubmed/37304472 http://dx.doi.org/10.1007/s12288-023-01635-4

Ejemplares similares

Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia
por: Chandrakala, S., et al.
Publicado: (2022)

Expression, purification and biological activity assessment of romiplostim biosimilar peptibody
por: Fayaz, Shima, et al.
Publicado: (2016)

A randomized, double‐blind, comparative study of the pharmacodynamics and pharmacokinetics of GP40141 (romiplostim biosimilar) and reference romiplostim in healthy male volunteers
por: Makarenko, Igor, et al.
Publicado: (2023)

Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia
por: Soff, Gerald A., et al.
Publicado: (2019)

The role of romiplostim for pediatric patients with immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2020)

Quality by Design in Downstream Process Development of Romiplostim
por: Pouri, Saeedeh, et al.
Publicado: (2022)

Romiplostim use in pregnant women with immune thrombocytopenia
por: Bussel, James B., et al.
Publicado: (2022)

Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency
por: Palandri, Francesca, et al.
Publicado: (2012)

Assessment of immunogenicity of romiplostim in clinical studies with ITP subjects
por: Jawa, Vibha, et al.
Publicado: (2010)

Romiplostim as a treatment for immune thrombocytopenia: a review
por: Chalmers, Sarah, et al.
Publicado: (2015)

Role of romiplostim in splenectomized and nonsplenectomized patients with immune thrombocytopenia
por: Perdomo, Jose
Publicado: (2016)

Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim
por: Pecci, Alessandro, et al.
Publicado: (2017)

A Review of Romiplostim Mechanism of Action and Clinical Applicability
por: Bussel, James B, et al.
Publicado: (2021)

Myelofibrosis Associated with Romiplostim Treatment in a Patient with Immune Thrombocytopenia
por: Gonzalez, Maria Fernanda, et al.
Publicado: (2012)

Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland
por: Lee, Dawn, et al.
Publicado: (2013)

Romiplostim for the Emergency Management of Severe Immune Thrombocytopenia with Intracerebral Hemorrhage
por: Gellens, Romain, et al.
Publicado: (2018)

Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia
por: Vishnu, Prakash, et al.
Publicado: (2016)

Treatment of 5 dogs with immune-mediated thrombocytopenia using Romiplostim
por: Kohn, Barbara, et al.
Publicado: (2016)

Romiplostim and Eltrombopag in Immune Thrombocytopenia as a Second-Line Treatment
por: Bidika, Erjola, et al.
Publicado: (2020)

Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopenia
por: Grainger, John D., et al.
Publicado: (2021)

Romiplostim for chemotherapy‐induced thrombocytopenia: Efficacy and safety of extended use
por: Wilkins, Cy R., et al.
Publicado: (2022)

Erratum to: Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland
por: Lee, Dawn, et al.
Publicado: (2013)

Erratum to: treatment of 5 dogs with immune-mediated thrombocytopenia using romiplostim
por: Kohn, Barbara, et al.
Publicado: (2016)

Successful Percutaneous Nephrolithotomy in Patients with Immune-Mediated Thrombocytopenia Treated with Romiplostim
por: McCall, Andrew N., et al.
Publicado: (2016)

Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia
por: Cines, Douglas B., et al.
Publicado: (2017)

Romiplostim for the Treatment of Immune Thrombocytopenia: Spotlight on Patient Acceptability and Ease of Use
por: Gilbert, Megan M, et al.
Publicado: (2020)

Azathioprine/immune-globulin/methylprednisolone/romiplostim: Lack of efficacy: case report
Publicado: (2021)

Recovery of Bone Marrow Function in VEXAS Syndrome-potential Role for Romiplostim
por: Al-Hakim, Adam, et al.
Publicado: (2023)

Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim
por: Michel, Marc, et al.
Publicado: (2011)

Total remission of severe immune thrombocytopenia after short term treatment with romiplostim
por: Vlachaki, Efthymia, et al.
Publicado: (2011)

High Doses of Romiplostim Induce Proliferation and Reduce Proplatelet Formation by Human Megakaryocytes
por: Currao, Manuela, et al.
Publicado: (2013)

New synergistic efficacy of combination of romiplostim and steroid in refractory immune thrombocytopenia patients
por: Yoon, Jun Seok, et al.
Publicado: (2018)

Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long‐term safety and efficacy
por: Fenaux, Pierre, et al.
Publicado: (2017)

Romiplostim-related myelofibrosis in refractory primary immune thrombocytopenia: A Case report
por: Kim, Hyun-Young, et al.
Publicado: (2019)

Immunomodulation in Primary Immune Thrombocytopenia: A Possible Role of the Fc Fragment of Romiplostim?
por: Schifferli, Alexandra, et al.
Publicado: (2019)

Efficacy and quality of life of Romiplostim in adults and children with immune thrombocytopenia: A review
por: He, Xin, et al.
Publicado: (2022)

Safety and efficacy of romiplostim in children and adolescents with Immune thrombocytopenia: A systematic review
por: de Oliveira, Fernanda Lubiana, et al.
Publicado: (2023)

The thrombopoietin mimetic romiplostim leads to the complete rescue of mice exposed to lethal ionizing radiation
por: Yamaguchi, Masaru, et al.
Publicado: (2018)

Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia
por: Tremblay, Gabriel, et al.
Publicado: (2018)

Assessment of romiplostim immunogenicity in adult patients in clinical trials and in a global postmarketing registry
por: Mytych, Daniel T., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_uettvldiei2pv4d2t5bqliodgi